Delcath Systems (NASDAQ:DCTH) Director Bridget Martell Sells 22,500 Shares of Company Stock

Delcath Systems, Inc. (NASDAQ:DCTH) Director Bridget Martell sold 22,500 shares of Delcath Systems stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $21.71, for a total value of $488,475.00. Following the sale, the director directly owned 22,500 shares of the company’s stock, valued at approximately $488,475. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Delcath Systems Price Performance

DCTH traded down $0.83 during trading on Friday, hitting $20.55. The stock had a trading volume of 675,186 shares, compared to its average volume of 734,330. The company has a 50 day moving average price of $15.88 and a 200-day moving average price of $12.70. The firm has a market cap of $714.93 million, a price-to-earnings ratio of 128.44 and a beta of 0.62. Delcath Systems, Inc. has a one year low of $8.12 and a one year high of $22.51.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. The firm had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. As a group, sell-side analysts predict that Delcath Systems, Inc. will post 0.13 EPS for the current fiscal year.

Key Delcath Systems News

These are some of the DCTH news items that stood out recently:

• Positive Sentiment: Zacks Research upgraded DCTH from “hold” to “strong-buy.” Zacks also cited the stock’s recent price strength and momentum, while noting that estimate revisions may support the trend. Zacks price-strength article
• Neutral Sentiment: Delcath will be featured on “Health Uncensored with Dr. Drew” in a segment about liver-directed cancer treatment. The coverage may raise awareness, but no direct commercial or financial impact was disclosed. BioSpace announcement
• Negative Sentiment: A separate report said an analyst reduced its Q2 EPS forecast; details of the revised estimate were not provided. Analyst forecast report

Institutional Trading of Delcath Systems

Several large investors have recently modified their holdings of DCTH. Entropy Technologies LP bought a new position in shares of Delcath Systems in the third quarter worth $328,000. Jump Financial LLC grew its stake in Delcath Systems by 6.3% during the third quarter. Jump Financial LLC now owns 93,589 shares of the company’s stock worth $1,495,000 after buying an additional 5,554 shares in the last quarter. Marshall Wace LLP grew its stake in Delcath Systems by 69.8% during the third quarter. Marshall Wace LLP now owns 371,893 shares of the company’s stock worth $5,939,000 after buying an additional 152,930 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Delcath Systems by 31.1% during the third quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after buying an additional 21,069 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in Delcath Systems by 30.3% in the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock valued at $729,000 after buying an additional 10,600 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DCTH has been the subject of several analyst reports. Zacks Research upgraded shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research report on Thursday. Wall Street Zen upgraded shares of Delcath Systems from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HC Wainwright raised their target price on shares of Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Finally, BTIG Research lifted their price target on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $29.33.

Delcath Systems Company Profile

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.